TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04148118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1010: 50 µg - sprayer - IN
Description: 20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1010: 50 µg - pipette - IN
Description: 20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1010: 100 µg - sprayer - IN
Description: 20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1010: 100 µg - pipette - IN
Description: 20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo) - sprayer - IN
Description: Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo) - pipette - IN
Description: Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax (positive control) - SC
Description: BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart.
Study: NCT01648036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Dose 5000 IU, subcutaneous, daily
Study: NCT00302523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: FK506,0.1mg/kg/d
Study: NCT02187289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Night-time compression bandages
Description: Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Sleeve, daytime wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Sleeve, daytime wear
Study: NCT00671125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
Study: NCT04424914

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Scintigraphy
Description: scintigraphy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Scintigraphy
Description: scintigraphy
Study: NCT00671099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Polyunsaturated Fatty Acid
Description: A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00869583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents \[METS\]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
Study: NCT03047564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated Total Knee Arthroplasty
Description: Implantation of a coated Total Knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Knee Arthroplasty
Description: Implantation of a Standard Total Knee Arthroplasty
Study: NCT04527978

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Nesofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Nesofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study: NCT02924805

Intervention type: OTHER
Intervention: Telemedical care
Description: Telemedically guided care based on a standard operating procedure
Study: NCT01038752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin Drug:Docetaxel Drug: Carboplatin
Description: Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug: Docetaxel Drug: Carboplatin
Description: Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
Study: NCT00714155

Intervention type: OTHER
Intervention: Questionnaires, Physical Examination
Description: Questionnaires, Physical Examination

Intervention type: OTHER
Intervention: Questionnaires, Physical Examination
Description: Questionnaires, Physical Examination
Study: NCT01267422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2-ND4
Description: injection
Study: NCT01608191

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT follow up
Description: 11 weeks programme conducted via internet. CBT with focus on weight stability.
Study: NCT02362152

Intervention type: DRUG
Intervention: Ingenol mebutate
Description: Topical field treatment as prescribed by dermatologist

Intervention type: DRUG
Intervention: 5-fluorouracil
Description: Topical field treatment as prescribed by dermatologist

Intervention type: DRUG
Intervention: Imiquimod
Description: Topical field treatment as prescribed by dermatologist

Intervention type: DRUG
Intervention: Diclofenac
Description: Topical field treatment as prescribed by dermatologist
Study: NCT03358381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the gap balance type of total knee arthroplasty
Description: A gap balance type of total knee arthroplasty surgery will be performed.The gap balance group will receive this kind of intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the measured resection type of total knee arthroplasty
Description: A measured resection type of total knee arthroplasty surgery will be performed.The measured resection group will receive this kind of intervention.
Study: NCT02700880

Intervention type: DEVICE
Intervention: LifeVest
Description: LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
Study: NCT01317524

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Homogenized milk
Description: 900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unhomogenized milk
Description: 900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skimmed Milk
Description: 900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
Study: NCT00413933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive Multidisciplinary Intervention
Description: Comprehensive Multidisciplinary Intervention
Study: NCT03470623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioabsorbable screws
Description: Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the bioabsorbable screw

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: steel screws
Description: Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the steel screw
Study: NCT03647072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP Plus Lanzoprazole
Description: CHOP plus Lanzoprazole 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP Plus Famotidine
Description: CHOP Plus Famotidine 40 mg
Study: NCT01903993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants received starting dose of 75 mg/m\^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
Study: NCT02187289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Sleeve, daytime wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Night-time Compression custom-made garment
Description: Standard Care plus night-time compression by a custom-made night time compression system garment.
Study: NCT02033473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: An apelin clamp in which an apelin infusion will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apelin
Description: An apelin clamp in which an apelin infusion will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A clamp reference during which a placebo solution (saline solution) will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A clamp reference during which a placebo solution (saline solution) will be administered
Study: NCT00677768

Intervention type: OTHER
Intervention: No intervention
Description: Sample collection

Intervention type: OTHER
Intervention: No intervention
Description: Sample collection

Intervention type: OTHER
Intervention: No intervention
Description: Sample collection

Intervention type: OTHER
Intervention: No intervention
Description: Sample collection
Study: NCT01200498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
Study: NCT05815706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDELA Supplemental nursing system
Description: The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
Study: NCT02444728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg BID for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg BID for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1000mg intravenous infusion every month for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
Study: NCT04122482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Course
Description: The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Course
Description: The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
Study: NCT03585686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: vemurafenib 20 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m2/12 h, days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine
Description: 6 mg/m2/d, days 1-5
Study: NCT03040830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 100 IM/day
Description: Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 100 IM/day
Description: Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
Study: NCT00810342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity tailored
Description: tailored telephone counseling, email feedback, and website resources over 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical activity standard
Description: standard print and website information on how to become more active
Study: NCT03659383

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optimal hypoglycemic treatment
Description: Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
Study: NCT01903993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram \[mg/kg\]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
Study: NCT03739580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)
Description: for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)
Description: for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
Study: NCT01793077

Intervention type: DRUG
Intervention: Depo-Eligard®
Description: Subcutaneous
Study: NCT01447199

Intervention type: BEHAVIORAL
Intervention: Health and Diet Questionnaire
Description: Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.

Intervention type: BEHAVIORAL
Intervention: Health and Diet Questionnaire
Description: Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.

Intervention type: BEHAVIORAL
Intervention: Health and Diet Questionnaire
Description: Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
Study: NCT00755456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD solution containing glucose
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD solution containing glucose and L-carnitine
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
Study: NCT01918371

Intervention type: DRUG
Intervention: Anti-VEGF
Description: Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.

Intervention type: DRUG
Intervention: Anti-VEGF
Description: Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
Study: NCT01382862

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Emergency Mobile Unit (STEMO)
Description: Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
Study: NCT00243022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract
Description: given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cyanocobalamin
Description: given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cyanocobalamin
Description: given orally
Study: NCT02787447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Hypofractionated Radiotherapy
Description: 40-45 Gy/5-15f

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha 1
Description: Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
Study: NCT02126462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel®

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine co-administered with saline
Study: NCT02782611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENHANCE: Enduring Happiness and Continued Self-Enhancement
Description: ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
Study: NCT01140282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Administered within 3 days of baseline testing and at post-trial visit